CN Mobile Logo

Search form


Hematologic Malignancies

Hematologic Malignancies

Adolescents and young adults with leukemia experienced inferior outcomes compared with children, especially if they were treated outside of a specialized cancer center.

Patients with chronic lymphocytic leukemia who discontinue treatment with ibrutinib due to disease progression or transformation had significantly worse survival compared with patients who discontinued therapy because of intolerance.

This article reviews newly approved drugs for hematologic malignancies: their indications, mechanisms of action, accompanying pivotal trial data, pertinent toxicities, use in special populations, and appropriate clinical context.

A 60-year-old man with a history of coronary artery disease and JAK2 V617F–positive polycythemia vera presented to our bone marrow transplantation clinic with progressive fatigue, splenomegaly, and cytopenias.

There was no association between conventional response outcomes, such as complete response or very good partial response, and survival in patients with newly diagnosed multiple myeloma.

The use of the thrombopoietin receptor agonist eltrombopag was clinically effective at raising platelet counts in patients with lower-risk myelodysplastic syndromes with severe thrombocytopenia.

Upfront treatment with melphalan and ASCT should be the standard treatment approach for younger patients with newly diagnosed multiple myeloma.


Subscribe to Hematologic Malignancies on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.